As reported by Reuters this afternoon, shares of STI Next Wave portfolio holding Lattice Semiconductor (LSCC) jumped nearly 20% today after Tsinghua Unigroup, a China-based investment company, revealed that it has purchased a 6% stake in the company. That’s good news for LSCC, but bad news for STI Investments… Read More
Jim Pearce is the Chief Investment Strategist of Personal Finance, our flagship publication, and manages two trading services, PF Pro and Mayhem Trader. He began his career as a stockbroker in 1983 and over the years has managed client investment portfolios for major banks, brokerage firms, and investment advisors. Jim earned a BA from The College of William & Mary and the CFP designation from the College of Financial Planning.
Analyst Articles
As reported by Reuters this afternoon, shares of STI Next Wave portfolio holding Lattice Semiconductor (LSCC) jumped nearly 20% today after Tsinghua Unigroup, a China-based investment company, revealed that it has purchased a 6% stake in the company. That’s good news for LSCC, but bad news for STI Investments… Read More
Its no secret that embattled Yahoo (YHOO) CEO Marissa Mayer is under the gun to prove to shareholders that she should remain in her leadership position with the company. However, in this case its not only the CEO that is under the microscope, but the company’s entire board of directors… Read More
Its no secret that embattled Yahoo (YHOO) CEO Marissa Mayer is under the gun to prove to shareholders that she should remain in her leadership position with the company. However, in this case its not only the CEO that is under the microscope, but the company’s entire board of directors… Read More
This week the U.S. Labor Department issued new regulations that mandate your financial advisor to conform to a “fiduciary standard” when recommending investment products for retirement plans.Unlike the previous standard of “suitability”, which only required that a recommended product not be inappropriate for a client, a fiduciary level of… Read More
Only three weeks ago we noted that the exoskeleton industry had made a number of significant advancements recently (“A Step in the Right Direction“). Since then one of our three exoskeleton stocks, Ekso Bionics (EKSO), got another big boost when it announced earlier this week that it received FDA… Read More
Only three weeks ago we noted that the exoskeleton industry had made a number of significant advancements recently (“A Step in the Right Direction“). Since then one of our three exoskeleton stocks, Ekso Bionics (EKSO), got another big boost when it announced earlier this week that it received FDA… Read More
The Fed is getting smarter, cars are getting smarter, and we're getting smarter (and richer!) right along with them. Read More
The Fed is getting smarter, cars are getting smarter, and we're getting smarter (and richer!) right along with them. Read More
Special Situations Portfolio Update – Argos TherapeuticsFor those of you participating in our current cancer treatment play (“One Little Shot to Kill Cancer Dead“), tomorrow is an important day. One of the three stocks we recommend in that bundle – Argos Therapeutics (ARGS) – is releasing its fourth quarter… Read More